Dr. Boxer received his MD and PhD degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed an internship in Internal Medicine at California Pacific Medical Center and a residency in Neurology at Stanford University Medical Center. He completed a fellowship in behavioral neurology at UCSF.
Dr. Boxer is an Associate Professor of Neurology and the Vera and John Graziadio Scholar in Alzheimer’s Disease Research. He directs the Alzheimer’s Disease and Frontotemporal Dementia Clinical Trials Program at the Memory and Aging Center. He participates in the evaluation and management of patients in the Memory and Aging Clinic and attends on the Moffitt Inpatient Neurology Service.
Dr. Boxer’s research uses quantitative eye movement (watch a video on this study) and neuroimaging (MRI and PET) measurements to study the pathophysiology of cognitive and motor impairments in normal aging, mild cognitive impairment, Alzheimer’s disease, frontotemporal lobar degeneration, progressive supranuclear palsy (PSP) and corticobasal degeneration. He is the lead principal investigator of the first US multicenter, randomized, placebo-controlled, clinical trial of a therapeutic agent for frontotemporal dementia (memantine/Namenda®) and an international, phase 2/3, randomized, placebo-controlled trial of the microtubule stabilizing agent, davunetide (NAP, Al-108), for PSP. Dr. Boxer is the recipient of the 2002 Edwin Boldrey Award from the San Francisco Neurological Society, the 2005 John Douglas French Foundation Alzheimer’s Award and a 2009 Hellman Foundation Scientist Award. He also leads the FTD Treatment Study Group (FTSG), a group looking to speed the development of new therapies for FTD.
Michael Geschwind, MD, PhD
Dr. Geschwind received his MD and PhD (neuroscience) degrees through the National Institutes of Health-sponsored Medical Scientist Training Program at the Albert Einstein College of Medicine in New York. He completed his internship in internal medicine at the University of California, Los Angeles Medical Center, his neurology residency at the Johns Hopkins University School of Medicine in Baltimore and his fellowship in behavioral neurology at the UCSF Memory and Aging Center (MAC). He has been at the Memory and Aging Center since 2003.
Dr. Geschwind evaluates patients in the MAC new patient clinic and participates in the management and care for these patients in the MAC continuity clinic. He is active in the training of medical students and residents at UCSF. Dr. Geschwind teaches a national course and lectures, both nationally and internationally, on the assessment of rapidly progressive dementias, including human prion diseases.
Dr. Geschwind’s primary research interest is the assessment and treatment of rapidly progressive dementias, including prion diseases such as Creutzfeldt-Jakob disease (CJD). Dr. Geschwind helped establish an inpatient hospital program for the assessment of rapidly progressive dementias at UCSF, one of the first of its kind in the country. He ran the first ever US treatment study for CJD. He also has an active research interest in cognitive dysfunction in movement disorders, such as Huntington’s disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and other Parkinsonian dementias.